Background
BRAF V600E mutations are present in approximately 8% to 12% of patients with metastatic colorectal cancer (mCRC). This subtype carries a poor prognosis and responds poorly to conventional chemotherapy. Although the dual-targeted regimen of encorafenib plus cetuximab has already been recognized, the optimal backbone chemotherapy to combine with it for first-line treatment remains a focus of clinical investigation.
BREAKWATER is a global, multicenter, open-label Phase 3 trial. Cohort 3 enrolled 147 patients with previously untreated BRAF V600E-mutant mCRC, randomized 1:1 to encorafenib + cetuximab + FOLFIRI (n=73) or FOLFIRI ± bevacizumab (n=74). The primary endpoint was objective response rate (ORR) by blinded independent central review (BICR). Key secondary endpoints included progression-free survival (PFS) by BICR; additional secondary endpoints were overall survival (OS), duration of response (DOR), and safety.
Methods
1. Study Design
Cohort 3 of BREAKWATER randomized 147 patients with previously untreated BRAF V600E-mutant mCRC 1:1 to the experimental arm (encorafenib + cetuximab + FOLFIRI, n=73) or the control arm (FOLFIRI ± bevacizumab, n=74).
2. Endpoints
The primary endpoint was BICR-assessed ORR. The key secondary endpoint was BICR-assessed PFS. Other secondary endpoints included OS, DOR, and safety.
Results
A data cutoff of 6 January 2026 showed breakthrough efficacy for the combination.
1. Efficacy
ORR: The experimental arm achieved a significantly higher ORR than the control arm (65.8% vs 40.5%), with an odds ratio (OR) of 2.779 (P=0.0011), indicating that the combination nearly tripled patients’ odds of achieving tumor shrinkage.
PFS: Median PFS reached 15.2 months in the experimental arm versus 8.3 months in the control arm. The risk of disease progression or death was reduced by 56% (HR=0.44, P=0.0002). Twelve-month PFS rates were 70.7% versus 30.5%, respectively, with a clear and durable separation of the curves.
OS: Median OS in the experimental arm had not yet been reached (NE), versus 20.3 months in the control arm. The risk of death was significantly reduced by 44% (HR=0.56, P=0.0131). The 18-month OS rates were 72.0% versus 54.5%, indicating a clear survival benefit trend.
Subgroup analysis: Clinical benefit in ORR and PFS was consistent across subgroups defined by age, sex, ECOG performance status, primary tumor site (left- vs right-sided colon), and baseline liver metastases.
2. Safety
The safety profile of the combination was consistent with the known profiles of the individual agents, with no new safety signals identified.
Adverse events (AEs): Treatment-emergent adverse event (TEAE) rates were similar between arms (98.6% vs 95.6%). The most common TEAEs included nausea, diarrhea, vomiting, and anemia.
Severity: Grade ≥3 TEAE rates were 70.4% in the experimental arm versus 80.9% in the control arm.
Tolerability: Despite the addition of more agents, the rate of permanent discontinuation due to TEAEs was not substantially increased (15.5% vs 10.3%), suggesting that the regimen is manageable in clinical practice.
Highlights
1. Filling the Chemotherapy-Backbone Gap
Prior studies have focused primarily on FOLFOX-based backbones. The current study confirms the strong efficacy of the dual-targeted combination with a FOLFIRI-based backbone, offering clinicians a potent “oxaliplatin-free”regimen, particularly suitable for patients with concerns about neurotoxicity or those who have previously received adjuvant oxaliplatin.
2. Impressive Survival Data
Median OS in the experimental arm has not yet been reached, and the 18-month survival rate exceeds 70% — a rare and encouraging finding in this high-risk BRAF-mutant population.
3. Potent Tumor Shrinkage
An ORR approaching 66% means the regimen is well suited to conversion therapy, helping patients with potentially resectable disease reach surgery.
Conclusion
BREAKWATER Cohort 3 confirms that encorafenib + cetuximab + FOLFIRI, compared with FOLFIRI ± bevacizumab, delivers clinically meaningful and statistically significant improvements in ORR and PFS, with a clear trend toward OS benefit, in the first-line treatment of BRAF V600E-mutant mCRC. The regimen is tolerable and may establish a new first-line standard for patients with BRAF V600E-mutant mCRC, further enriching the armamentarium of individualized treatment.
Reference
[1] Kopetz S, Tabernero J, Lonardi S, et al. A randomised study of encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer: BREAKWATER Cohort 3. Ann Oncol. 2026.